SEC Filing Summary: Pieris Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pieris Pharmaceuticals, Inc. on January 11, 2015. The registrant is a Nevada corporation with principal executive offices in Freising-Weihenstephan, Germany. The report discloses a specific corporate governance event regarding the company's independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a change in the certifying accountant and does not contain financial performance data for the period.
Material Changes
The primary material change disclosed is the appointment of a new independent registered public accounting firm:
- New Auditor: Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft (E&Y) was engaged on January 11, 2015.
- Scope: E&Y will act as the principal accountant to audit the Company's financial statements.
- Prior Relationship: E&Y previously audited Pieris AG (now a wholly-owned subsidiary) for the years ended December 31, 2013 and 2012.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or discussion of risks and contingencies related to operations. Regarding the auditor change, the company confirmed that during the two most recent fiscal years and through the date of engagement:
- No consultations occurred with E&Y regarding the application of accounting principles or the type of audit opinion.
- No written reports or oral advice were provided by E&Y that were important factors in reaching decisions on accounting or financial reporting issues.
- There were no disagreements or reportable events relating to the Company.
Investor Verification Checklist
- Verify the transition timeline between the previous auditor and E&Y to ensure no gaps in audit coverage.
- Review the previously filed Form 8-K from December 18, 2014 (Exhibits 99.1 and 99.2) to understand the historical financial statements audited by E&Y for the subsidiary.
- Confirm the status of the prior independent registered public accounting firm and the reasons for their departure, if disclosed in other filings.